On 28 August 2026, DualityBio announced that it has entered into a global collaboration and licence agreement with Genentech to develop antibody-drug conjugates (ADCs) utilising the “DualityBio Unique Payload Antibody Conjugate” (DUPAC) platform.
Under the agreement, China-based Duality will generate and develop ADCs against US-based Genentech’s defined oncology targets using payloads from the DUPAC platform and will lead discovery and early global clinical development. Genentech will receive an exclusive global licence and will assume sole responsibility for clinical development and commercialisation after Phase 1a.
Duality will receive an upfront payment of US$45 million and is eligible to receive more than US$1 billion in aggregate milestone payments, plus tiered royalties on annual net sales of approved products.
Between 2023 and 2025, Duality entered into licence and commercialisation agreements with BioNTech, GSK, BeOne Medicines (formally BeiGene) and Avenzo Therapeutics in relation to Duality’s ADCs. In April 2023, Duality and BioNTech entered into an exclusive licence and collaboration agreement for two ADC assets (DB-1303 and DB-1311). In July 2023, Duality and BeOne Medicines (formally BeiGene) entered into an exclusive option for a global clinical and commercial licence agreement for an ADC for patients with solid tumours. In December 2024, Duality and GSK entered into an exclusive option to obtain a licence to develop and commercialise DB-1324. In January 2025, Duality and Avenzo Therapeutics entered into an exclusive global licence and commercialisation agreement for AVZO-1418/DB-1418.